Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

Hézode, C; Hirschfield, Gm; Ghesquiere, W; Sievert, W; Rodriguez Torres, M; Shafran, Sd; Thuluvath, Pj; Tatum, Ha; Waked, I; Esmat, G; Lawitz, Ej; Rustgi, Vk; Pol, S; Weis, N; Pockros, Pj; Bourlière, M; Serfaty, L; Vierling, Jm; Fried, Mw; Weiland, O; Brunetto, Maurizia Rossana; Everson, Gt; Zeuzem, S; Kwo, Py; Sulkowski, M; Bräu, N; Hernandez, D; McPhee, F; Wind Rotolo, M; Liu, Z; Noviello, S; Hughes, Ea; Yin, Pd; Schnittman, S.

doi:10.1136/gutjnl-2014-307498

OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype 1 (N=365) or 4 (N=30) infection were randomly assigned (2:2:1) to daclatasvir 20 mg or 60 mg, or placebo once daily plus weekly peginterferon-alfa-2a and twice-daily ribavirin. Daclatasvir recipients achieving protocol-defined response (PDR; HCV-RNA

Autori interni:	Hézode C Hirschfield GM Ghesquiere W Sievert W Rodriguez Torres M Shafran SD Thuluvath PJ Tatum HA Waked I Esmat G Lawitz EJ Rustgi VK Pol S Weis N Pockros PJ Bourlière M Serfaty L Vierling JM Fried MW Weiland O BRUNETTO, MAURIZIA ROSSANA Everson GT Zeuzem S Kwo PY Sulkowski M Bräu N Hernandez D McPhee F Wind Rotolo M Liu Z Noviello S Hughes EA Yin PD Schnittman S. mostra contributor esterni nascondi contributor esterni
Autori:	Hézode, C; Hirschfield, Gm; Ghesquiere, W; Sievert, W; Rodriguez Torres, M; Shafran, Sd; Thuluvath, Pj; Tatum, Ha; Waked, I; Esmat, G; Lawitz, Ej; Rustgi, Vk; Pol, S; Weis, N; Pockros, Pj; Bourlière, M; Serfaty, L; Vierling, Jm; Fried, Mw; Weiland, O; Brunetto, MAURIZIA ROSSANA; Everson, Gt; Zeuzem, S; Kwo, Py; Sulkowski, M; Bräu, N; Hernandez, D; Mcphee, F; Wind Rotolo, M; Liu, Z; Noviello, S; Hughes, Ea; Yin, Pd; Schnittman, S.
Titolo:	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
Anno del prodotto:	2015
Abstract:	OBJECTIVE: To evaluate the safety and efficacy of daclatasvir, an HCV NS5A inhibitor with pangenotypic activity, administered with peginterferon-alfa-2a/ribavirin. DESIGN: In this Phase 2b double-blind, placebo-controlled study, treatment-naive adults with HCV genotype 1 (N=365) or 4 (N=30) infection were randomly assigned (2:2:1) to daclatasvir 20 mg or 60 mg, or placebo once daily plus weekly peginterferon-alfa-2a and twice-daily ribavirin. Daclatasvir recipients achieving protocol-defined response (PDR; HCV-RNA
Digital Object Identifier (DOI):	10.1136/gutjnl-2014-307498
Appare nelle tipologie:	1.1 Articolo in rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

CINECA IRIS Institutional Research Information System

File in questo prodotto: